Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL959665 | 1.00 | CA1 (0.45) | CA1CA2CA4CA9KEAP1 | |
| SCHEMBL960002 | 0.83 | ALDH1A1 (0.47) | CA1CA2CA4CA9SMN1; SMN2 | |
| SCHEMBL960003 | 0.83 | ALDH1A1 (0.47) | CA1CA2CA4CA9SMN1; SMN2 | |
| SCHEMBL3558787 | 0.83 | UGCG (0.39) | CA1CA2CA4CA9SMN1; SMN2 | |
| SCHEMBL3558789 | 0.83 | UGCG (0.39) | CA1CA2CA4CA9SMN1; SMN2 | |
| SCHEMBL954142 | 0.82 | ALDH1A1 (0.45) | CA1CA2CA4CA9HSD11B1 | |
| SCHEMBL954141 | 0.82 | ALDH1A1 (0.45) | CA1CA2CA4CA9HSD11B1 | |
| SCHEMBL954452 | 0.82 | CA1 (0.46) | CA1CA2CA4CA9KEAP1 | |
| SCHEMBL954455 | 0.82 | CA1 (0.46) | CA1CA2CA4CA9KEAP1 | |
| SCHEMBL954453 | 0.82 | CA1 (0.46) | CA1CA2CA4CA9KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394797-B2 | Substituted pyrazole sigma receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-03-12 | — | — | US | disclosed |
| EP-1781619-B1 | SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2011-08-17 | — | — | EP | disclosed |
| US-20110015183-A1 | SUBSTITUTED PYRAZOLE SIGMA RECEPTOR ANTAGONISTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-01-20 | — | — | US | disclosed |
| US-7829559-B2 | Substituted pyrazole sigma receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-11-09 | — | — | US | disclosed |
| WO-2010066829-A1 | PROCESS FOR OBTAINING ENANTIOMERICALLY ENRICHED PYRAZOLE DERIVATIVES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-06-17 | — | — | WO | disclosed |
| EP-2196458-A1 | Process for obtaining enantiomerically enriched pyrazole derivatives | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-06-16 | — | — | EP | disclosed |
| US-7282499-B2 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-10-16 | — | — | US | disclosed |
| US-20070232585-A1 | Sigma Receptor Inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-10-04 | — | — | US | disclosed |
| EP-1781619-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-09 | — | — | EP | disclosed |
| EP-1634873-A1 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-15 | — | — | EP | disclosed |
| US-20060047127-A1 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-02 | — | — | US | disclosed |
| WO-2006021463-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015183-A1 | SUBSTITUTED PYRAZOLE SIGMA RECEPTOR ANTAGONISTS | SIGMAR1, OPRK1, OPRD1 | CA1 4683/4885CA2 4750/4885CA4 4875/4885 |
| US-20070232585-A1 | Sigma Receptor Inhibitors | SIGMAR1, OPRK1, OPRL1 | CA1 4673/4885CA2 4680/4885CA4 4874/4885 |
| US-20060047127-A1 | Sigma receptor inhibitors | SIGMAR1, OPRK1, OPRL1 | CA1 4788/4885CA2 4780/4885CA4 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.